Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy. (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2025)